Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390541 | 1.00 | ALDH1A1 (0.63) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10470169 | 0.94 | RAB9A (0.59) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469568 | 0.94 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469211 | 0.93 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10470174 | 0.92 | KMT2A (0.68) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL11108904 | 0.92 | KMT2A (0.66) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469152 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469519 | 0.92 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469507 | 0.92 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL10469524 | 0.92 | HPGD (0.61) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907360-B1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LTD (IN) | 2011-03-30 | — | — | EP | claimed |
| US-20100184990-A1 | Process for the Manufacture of Flecainide | GLADE ORGANICS PRIVATE LIMITED (IN) | 2010-07-22 | — | — | US | claimed |
| US-20100056794-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-03-04 | — | — | US | claimed |
| EP-1907360-A4 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LTD (IN) | 2009-04-01 | — | — | EP | claimed |
| EP-1918280-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | claimed |
| EP-1907360-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | Glade Organics Private Limited (IN) | 2008-04-09 | — | — | EP | claimed |
| WO-2007003982-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LIMITED (IN) | 2007-01-11 | — | — | WO | claimed |
| US-6586598-B2 | Reacting 2,5-bis(2,2,2- trifluoroethoxy)- alpha , alpha -dibromo- alpha -chloro acetophenone with 2-(aminomethyl)pyridine to form 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide, and reducing | GENEVA PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| EP-1303489-A2 | ALPHA,ALPHA-DIBROMO-ALPHA-CHLORO-ACETOPHENONES AS SYNTHONS | GENEVA PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020188130-A1 | Alpha, alpha-dibromo-alpha-chloro-acetophenones as synthons | RAY ANUP K (US) | 2002-12-12 | — | — | US | claimed |
| US-6458957-B1 | PROCESS FOR PREPARING AN AROMATIC CARBONYL COMPOUND, WHICH COMPRISES (A) CONVERTING AN .ALPHA.-CHLORO DERIVATIVE OF AN ACETOPHENONE COMPOUND TO DIBROMO-.ALPHA.-CHLORO ACETOPHENONE COMPOUND AND (B) REACTING THE | GENEVA PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | claimed |
| WO-2002004419-A2 | α,α-DIBROMO-α-CHLORO-ACETOPHENONES AS SYNTHONS | GENEVA PHARMACEUTICALS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-4684733-A | Process for the preparation of intermediates of derivatives of pyrrolidine and piperidine | RIKER LABORATORIES, INC. (US) | 1987-08-04 | — | — | US | claimed |
| US-4650873-A | Process for the preparation of a derivative of piperidine | RIKER LABORATORIES (US) | 1987-03-17 | — | — | US | claimed |
| US-4617396-A | Process for the preparation of derivatives of piperidine | RIKER LABORATORIES, INC. (US) | 1986-10-14 | — | — | US | claimed |
| EP-2079674-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | GRINDEKS JSC (LV) | 2011-06-29 | — | — | EP | disclosed |
| EP-1907360-B1 | IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE | GLADE ORGANICS PRIVATE LTD (IN) | 2011-03-30 | — | — | EP | disclosed |
| US-4617396-A | Process for the preparation of derivatives of piperidine | RIKER LABORATORIES, INC. (US) | 1986-10-14 | — | — | US | disclosed |
| US-4013670-A | ANTIARRHYTHMICS | RIKER LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
| US-4005209-A | Antiarrhythmic method utilizing fluoroalkoxy-N-piperidyl and pyridyl benzamides | RIKER LABORATORIES, INC. (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056794-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF | BOLA2; BOLA2B, TET2, CYP1A2 | ALDH1A1 430/4885KDM4E 429/4885SMN1; SMN2 1097/4885 |
| US-20020188130-A1 | Alpha, alpha-dibromo-alpha-chloro-acetophenones as synthons | CYP2D6, CYP2B6, CYP2A6 | ALDH1A1 251/4885KDM4E 3023/4885SMN1; SMN2 1852/4885 |
| US-20100184990-A1 | Process for the Manufacture of Flecainide | KCND2, KCNH1, KCNH2 | ALDH1A1 960/4885KDM4E 478/4885SMN1; SMN2 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.